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LETTER TO THE EDITORProbiotic Soy Milk: A Call to ActionIN A RECENTLY published clinical trial, GhiasvandR et al1 have shown that the 8-week consumption of
200 mL/day probiotic soy milk fortified with Lactoba-
cillus plantarum A7 may exert favorable changes on bio-
markers of oxidative stress in patients with type 2
diabetes and concomitant diabetic kidney disease
(DKD).
Previous evidences highlighted the close relationship
between gut bacteria and oxidative stress and the potential
application of probiotic supplementation in individuals
with diabetes.2,3 It has been indeed pointed out that
these patients are characterized by low counts of some
beneficial gut microbials such as the obligate anaerobes
bacteria Lactobacillaceae and Bifidobacteriaceae.4 Since
the contribution of human gut microbiota appears to be
linked to increased levels of inflammatory markers and
mediators, there is supporting rationale at restoring the
regular gut microbiota by administering probiotics en-
riched with anaerobes bacteria5 (e.g., Lactobacillus rhamno-
sus and Enterococcus faecium). This, in turn, would exert
anti-inflammatory effects and ameliorate dysbiosis
through microRNAs modulation (e.g., upregulation of
miR-423-5p and miR-155).5 The antioxidative and
anti-inflammatory role of probiotics may also be benefi-
cial in patients with chronic kidney disease, as it would
reduce renotoxic bacterial products involved in acute
tubular necrosis such as p-cresol and trimethylamine
N-oxide.6
Ghiasvand R et al1 randomized 48 DKD patients to
soy milk or probiotic soy milk, adding a strain of Lacto-
bacillus plantarum 7 (KC 3555240 LA7) to pasteurized
plain soy milk, to test whether the 8-week consumption
of this product exerted favorable changes in the individ-
ual profile of oxidative biomarkers including malondial-
dehyde, 8-iso-prostaglandin F2a (8-iso-F2a), oxidized
glutathione (glutathione disulfide), glutathione (GSH),
glutathione peroxidase, and glutathione reductase.
Although the 2 subgroups had similar baseline levels of
these biomarkers, the fortified probiotic soy milk sub-
group showed significantly increased levels of GSH,
GSH-P, and glutathione reductase and lower levels of
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The authors claim that their results, although drawn
from a relatively limited sample size, may be clinically
relevant to reduce the oxidative stress in patients with
DKD. However, it remains to be tested whether these ef-
fects may last over time and whether the administered
dosage of fortified probiotic soy milk has any impact
on glycemic control, either expressed as fasting plasma
glucose, hemoglobin A1c, or 2-hour plasma glucose.
Since (sub)diabetic hyperglycemia in the context of
increased insulin resistance is characterized by a whole-
body inflammatory status and increased circulating levels
of free radical species, clarification of these aspects would
encourage a more extensive use of probiotic LA7 in
DKD patients.
Furthermore, a large proportion of patients included in
the study appeared to be on diet treatment only and no in-
formation is given on the ongoing oral hypoglycemic ther-
apy or on other noninsulin injectable drugs. It would be,
however, interesting to explore in larger datasets and
with longer follow-up duration, whether the impact of
fortified probiotic milk would hold significant or other-
wise change depending on the ongoing glucose-lowering
treatment. This would be relevant, particularly in light of
the advancements in the pharmacologic toolkit accrued
over the past decade and currently available for the treat-
ment of diabetes.
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